Cellosaurus cell line WM902B-BR (CVCL_VK52)

• Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289).
  
• Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Leu (c.71G>T); ClinVar=VCV000376377; Zygosity=Unspecified (PubMed=21156289).
  
• Mutation; HGNC; 11355; STAG2; Simple; p.Lys1083Ter (c.3247A>T); Zygosity=Unspecified (PubMed=27500726).
  

PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023
Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W., Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K., Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A., Sosman J.A., Nathanson K.L., Herlyn M.
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Cancer Cell 18:683-695(2010)

PubMed=27500726; DOI=10.1038/nm.4155
Shen C.-H., Kim S.H., Trousil S., Frederick D.T., Piris A., Yuan P., Cai L., Gu L., Li M., Lee J.H., Mitra D., Fisher D.E., Sullivan R.J., Flaherty K.T., Zheng B.
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
Nat. Med. 22:1056-1061(2016)